SLC5A2 and atrial fibrillation: Although SGLT-2 inhibitors are known to counteract occurrence of AF, reduce hepatic lipid accumulation and may attenuate fibrosis through various metabolic and anti-inflammatory pathways, the use of dapagliflozin has also been associated with a risk of renal-related adverse events, warranting careful patient selection and monitoring [115].